TY - JOUR T1 - Evaluation of transplacental transfer of mRNA vaccine products and functional antibodies during pregnancy and early infancy JF - medRxiv DO - 10.1101/2021.12.09.21267423 SP - 2021.12.09.21267423 AU - Mary Prahl AU - Yarden Golan AU - Arianna G. Cassidy AU - Yusuke Matsui AU - Lin Li AU - Bonny Alvarenga AU - Hao Chen AU - Unurzul Jigmeddagva AU - Christine Y. Lin AU - Veronica J. Gonzalez AU - Megan A. Chidboy AU - Lakshmi Warrier AU - Sirirak Buarpung AU - Amy P. Murtha AU - Valerie J. Flaherman AU - Warner C. Greene AU - Alan H.B. Wu AU - Kara L. Lynch AU - Jayant Rajan AU - Stephanie L. Gaw Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/12/13/2021.12.09.21267423.abstract N2 - Studies are needed to evaluate the safety and effectiveness of mRNA SARS-CoV-2 vaccination during pregnancy, and the levels of protection provided to their newborns through placental transfer of antibodies. We evaluated the transplacental transfer of mRNA vaccine products and functional anti-SARS-CoV-2 antibodies during pregnancy and early infancy in a cohort of 20 individuals vaccinated during pregnancy. We found no evidence of mRNA vaccine products in maternal blood, placenta tissue, or cord blood at delivery. However, we found time-dependent efficient transfer of IgG and neutralizing antibodies to the neonate that persisted during early infancy. Additionally, using phage immunoprecipitation sequencing, we found a vaccine-specific signature of SARS-CoV-2 Spike protein epitope binding that is transplacentally transferred during pregnancy. In conclusion, products of mRNA vaccines are not transferred to the fetus during pregnancy, however timing of vaccination during pregnancy is critical to ensure transplacental transfer of protective antibodies during early infancy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementM.P. was supported by the National Institutes of Health (NIAID K23AI127886), the Marino Family Foundation, and UCSF REAC award. Y.G. was supported by the Weizmann Institute of Science -National Postdoctoral Award Program for Advancing Women in Science, and of the International Society for Research in Human Milk and Lactation (ISRHML) Trainee Bridge Fund. Y.M. and W.C.G. were supported by The Roddenberry Foundation. S.L.G. was supported by the National Institutes of Health (NIAID K08AI141728), and the Bill and Melinda Gates Foundation (INV-017035), and a generous gift from the Kryzewski Family.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of California San Francisco (UCSF) institutional review board approved the study (20-32077).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -